Advancements in platform and technology developments for bispecific and multi-specific antibodies are leading to a profusion of new constructs and clinical candidates that are being vetted for their safety and efficacy in the clinic. A review of clinical and preclinical data will be featured at the 15th Annual Advancing Bispecifics and Combination Therapy to the Clinic: Novel and Synergistic Combinations, taking place 15 November 2023 in Lisbon, Portugal, at the 15th Annual PEGS Europe Summit. Industry leaders will be discussing translational approaches and optimization of candidates so they can advance them to the growing repertoire of successful bispecific antibody therapeutics that are FDA-approved and on the market.
Scientific Advisory Board:
Nicolas Fischer, PhD, CEO, Light Chain Bioscience
Pieter Fokko van Loo, PhD, Senior Director, Oncology – Immunology, Merus NV
Jeanette H.W. Leusen, PhD, Professor, Translational Immunology, Utrecht University
Paul WH Parren, PhD, Executive Vice President and Head, Research and Development, LAVA Therapeutics; Professor,
Molecular Immunology, Leiden University Medical Center
David E. Szymkowski, PhD, Vice President, Preclinical Operations, Xencor, Inc.